Aventis Pharma Ltd has paid Rs 567.1 crore as lumpsum consideration to Universal Medicare Pvt Ltd to acquire its marketing and distribution of branded nutraceutical formulations business in India for which it had earlier entered into a definitive agreement.
The transaction was closed on November 3 on fulfilment of all the conditions precedent and on closing, it paid a sum of Rs 567.1 crore as lumpsum consideration for the business as a going concern.